• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Achieve Life Sciences Inc.

    2/27/24 3:32:52 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ACHV alert in real time by email
    SC 13G 1 d10982711_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

     

    Achieve Life Sciences, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    004468500
    (CUSIP Number)

     

     

    November 15, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

     

    _____________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 004468500    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Patrick J. Callahan III  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,167,439  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,167,439  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,167,4391  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
             

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     


    1 This figure includes 639,146 warrants beneficially owned by the Reporting Person each exercisable for 1 share of Common Stock, par value $0.001 per share.

     
     

     

    CUSIP No 004468500    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Patrick J. Callahan III Trust  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Florida  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,067,439  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,067,439  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,067,4392  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.5%  
             

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     


    2 This figure includes 639,146 warrants beneficially owned by the Reporting Person each exercisable for 1 share of Common Stock, par value $0.001 per share.

     
     

     

    CUSIP No 004468500    

     

    Item 1. (a). Name of Issuer:  
           
        Achieve Life Sciences, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    22722 29th Drive SE, Suite 100, Bothell, WA 98021

     

    1040 West Georgia Street, Suite 1030, Vancouver, British Columbia, Canada V6E 4H1

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Patrick J. Callahan III

    Patrick J. Callahan III Trust

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

     

    Patrick J. Callahan III

    1189 Wilmette Avenue #216

    Wilmette, IL 60091

     

    Patrick J. Callahan III Trust

    c/o Patrick J. Callahan III

    1189 Wilmette Avenue #216

    Wilmette, IL 60091

     

     

     

      (c).

    Citizenship:

     

    Patrick J. Callahan III – United States citizen

    Patrick J. Callahan III Trust – Florida trust

       
       

     

      (d).   Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  

     

      (e). CUSIP Number:  
           
        004468500  

     

    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).

     

      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    2,167,439 shares deemed beneficially owned by Patrick J. Callahan III

    2,067,439 shares deemed beneficially owned by Patrick J. Callahan III Trust

     

      (b)   Percent of class:
         
       

    9.9% deemed beneficially owned by Patrick J. Callahan III

    9.5% deemed beneficially owned by Patrick J. Callahan III Trust

     

         
      (c) Number of shares as to which Patrick J. Callahan III has:
         
        (i) Sole power to vote or to direct the vote 0  
             
        (ii)   Shared power to vote or to direct the vote 2,167,439  
             
        (iii) Sole power to dispose or to direct the disposition of 0  
             
        (iv)   Shared power to dispose or to direct the disposition of 2,167,439  
         
       

     

    Number of shares as to which Patrick J. Callahan III Trust has:

     
           
        (i) Sole power to vote or to direct the vote 0  
             
        (ii)   Shared power to vote or to direct the vote 2,067,439  
                         

        (iii) Sole power to dispose or to direct the disposition of 0  
             
        (iv)   Shared power to dispose or to direct the disposition of 2,067,439  

     

     
     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].

     

      N/A
     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

      

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

      

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
         

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 27, 2024
      (Date)
         

     

    Patrick J. Callahan III

     

     

    By: /s/ Patrick J. Callahan III
    Name: Patrick J. Callahan III

     

         
    Patrick J. Callahan III Trust  

    By: /s/ Patrick J. Callahan III

    Name: Patrick J. Callahan III

    Title: Trustee

     

         

     

     

       

     

     

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated February 27, 2024 relating to the Common Stock, par value $0.001 per share of Achieve Life Sciences, Inc. shall be filed on behalf of the undersigned.

     

      February 27, 2024
      (Date)
         

     

    Patrick J. Callahan III

     

     

    By: /s/ Patrick J. Callahan III
    Name: Patrick J. Callahan III

     

         
    Patrick J. Callahan III Trust  

    By: /s/ Patrick J. Callahan III

    Name: Patrick J. Callahan III

    Title: Trustee

     

     

     

       
         

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $ACHV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACHV

    DatePrice TargetRatingAnalyst
    11/14/2024$12.00Buy
    Rodman & Renshaw
    9/27/2024$20.00Strong Buy
    Raymond James
    5/10/2023$8.00 → $20.00Buy
    Maxim Group
    10/4/2021$25.00Buy
    Alliance Global Partners
    6/23/2021$23.00Outperform
    Oppenheimer
    More analyst ratings

    $ACHV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Slaoui Kristen B.

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      6/10/25 5:01:26 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Phelan Nancy R.

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      6/10/25 4:58:23 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Sellig Thomas

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      6/10/25 4:55:20 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Achieve Life Sciences with a new price target

      Rodman & Renshaw initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00

      11/14/24 7:20:56 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Raymond James initiated coverage on Achieve Life Sciences with a new price target

      Raymond James initiated coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00

      9/27/24 7:26:18 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Maxim Group reiterated coverage on Achieve Life Sciences with a new price target

      Maxim Group reiterated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $20.00 from $8.00 previously

      5/10/23 11:34:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    SEC Filings

    See more
    • Achieve Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      6/27/25 5:28:32 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 424B5 filed by Achieve Life Sciences Inc.

      424B5 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      6/27/25 4:59:29 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 424B5 filed by Achieve Life Sciences Inc.

      424B5 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      6/26/25 4:15:40 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/6/24 4:49:23 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

      SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 16,766,666 shares of common stock at a public offering price of $3.00 per share and accompanying warrant, which includes common warrants to purchase up to 1,766,666 shares issued upon the partial exercise by the underwriters of their option to

      6/30/25 7:52:40 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

      SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common stock and accompanying common warrants were offered collectively at a price to the public of $3.00 per share and accompanying common warrant. Achieve has also granted the underwriters a 30-

      6/26/25 11:43:33 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Announces Proposed Underwritten Public Offering

      SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to

      6/26/25 4:03:00 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Leadership Updates

    Live Leadership Updates

    See more
    • Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

      SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea

      1/10/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

      SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, information technology, legal and other key administrative functions, ensuring effective planning and execution to support organizational objectives. "Mark's extensive financial, strategic, and opera

      12/9/24 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments

    $ACHV
    Financials

    Live finance-specific insights

    See more
    • Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

      Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully

      5/13/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

      Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Hig

      3/11/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/12/24 12:14:09 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Achieve Life Sciences Inc.

      SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/4/24 10:59:37 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Achieve Life Sciences Inc. (Amendment)

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      5/20/24 5:01:27 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care